• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS.

作者信息

Stengel Anna, Haferlach Torsten, Baer Constance, Hutter Stephan, Meggendorfer Manja, Kern Wolfgang, Haferlach Claudia

机构信息

MLL Munich Leukemia Laboratory, Munich, Germany.

出版信息

Blood Adv. 2023 Jul 11;7(13):2952-2956. doi: 10.1182/bloodadvances.2022009100.

DOI:10.1182/bloodadvances.2022009100
PMID:36735768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10320211/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/516f/10320211/2ae142d3d812/BLOODA_ADV-2022-009100-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/516f/10320211/2ff86abeca0e/BLOODA_ADV-2022-009100-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/516f/10320211/2ae142d3d812/BLOODA_ADV-2022-009100-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/516f/10320211/2ff86abeca0e/BLOODA_ADV-2022-009100-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/516f/10320211/2ae142d3d812/BLOODA_ADV-2022-009100-gr1.jpg

相似文献

1
Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS.TP53单打击和双打击事件在急性髓系白血病和骨髓增生异常综合征中的特定亚型分布及其对预后的影响
Blood Adv. 2023 Jul 11;7(13):2952-2956. doi: 10.1182/bloodadvances.2022009100.
2
TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.初诊急性髓系白血病和骨髓增生异常综合征中的 TP53 突变。
Diagn Pathol. 2021 Oct 31;16(1):100. doi: 10.1186/s13000-021-01162-8.
3
Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, deletion, and mutations.在急性髓细胞白血病和骨髓增生异常综合征中，双微体染色体与复杂核型、单体核型、缺失和突变相关。
Leuk Lymphoma. 2021 Oct;62(10):2466-2474. doi: 10.1080/10428194.2021.1919663. Epub 2021 Apr 27.
4
Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.5q 缺失类型与急性髓系白血病和骨髓增生异常综合征中复杂核型、克隆进化、TP53 突变状态和预后的相关性。
Genes Chromosomes Cancer. 2014 May;53(5):402-10. doi: 10.1002/gcc.22151. Epub 2014 Feb 3.
5
Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.伴有原始细胞过多的急性髓系白血病和骨髓增生异常综合征中突变型 TP53 的分子特征及预后
Int J Lab Hematol. 2023 Jun;45(3):344-352. doi: 10.1111/ijlh.14030. Epub 2023 Mar 1.
6
TP53 in MDS and AML: Biological and clinical advances.TP53 在 MDS 和 AML 中的作用：生物学和临床进展。
Cancer Lett. 2024 Apr 28;588:216767. doi: 10.1016/j.canlet.2024.216767. Epub 2024 Feb 27.
7
Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.TP53 突变型髓系肿瘤的诊断与管理现状及未来展望
Pathobiology. 2024;91(1):45-54. doi: 10.1159/000534566. Epub 2023 Oct 13.
8
Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.伴有 17 号染色体异常的急性髓系白血病或骨髓增生异常综合征，以及造血干细胞移植与否的长期预后。
Leuk Res. 2020 Aug;95:106402. doi: 10.1016/j.leukres.2020.106402. Epub 2020 Jun 18.
9
Variation characteristics and clinical significance of in patients with myeloid neoplasms.骨髓增生异常肿瘤患者中 的变化特征及临床意义。
Hematology. 2024 Dec;29(1):2387878. doi: 10.1080/16078454.2024.2387878. Epub 2024 Aug 14.
10
Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.AML-MRC 的分子特征分析显示，TP53 突变是一个不良预后因素，与 MRC 定义标准、TP53 等位基因状态或 TP53 变异等位基因频率无关。
Cancer Med. 2023 Mar;12(6):6511-6522. doi: 10.1002/cam4.5421. Epub 2022 Nov 16.

引用本文的文献

1
Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management.急性髓系白血病：诊断、治疗与管理的最新进展
Cancers (Basel). 2025 Jul 18;17(14):2387. doi: 10.3390/cancers17142387.
2
Comparison of mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression.骨髓发育异常和急性白血病中突变的比较表明，它们在起始和进展过程中发挥着不同的作用。
Blood Neoplasia. 2024 Feb 15;1(1):100004. doi: 10.1016/j.bneo.2024.100004. eCollection 2024 Mar.
3
Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML.

本文引用的文献

1
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.骨髓增生异常综合征的分子国际预后评分系统
NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.
2
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。
Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
3
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
异基因干细胞移植的发展：主要聚焦于急性髓系白血病
Cells. 2025 Apr 10;14(8):572. doi: 10.3390/cells14080572.
4
TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation.TP53突变体等位基因频率和细胞遗传学决定了MDS/AML移植的预后分组。
Blood Adv. 2025 Jun 10;9(11):2845-2854. doi: 10.1182/bloodadvances.2024014499.
5
Allogeneic hematopoietic cell transplantation in elderly patients with myelodysplastic syndromes: Considerations and challenges.老年骨髓增生异常综合征患者的异基因造血细胞移植：考量与挑战
Semin Hematol. 2024 Dec;61(6):420-430. doi: 10.1053/j.seminhematol.2024.10.004. Epub 2024 Oct 17.
6
Patients with -Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study.接受强化诱导治疗的携带 - 突变的急性髓系白血病患者因挽救治疗率较高而有更好的预后：一项单机构回顾性研究。
Cancers (Basel). 2024 Aug 7;16(16):2784. doi: 10.3390/cancers16162784.
7
Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS.TP53 等位基因状态、 blast 计数和复杂核型对 AML 和 MDS 患者生存的相互影响。
Blood Adv. 2023 Sep 26;7(18):5540-5548. doi: 10.1182/bloodadvances.2023010312.
8
TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.TP53 突变的骨髓增生异常综合征和急性髓系白血病。
Mediterr J Hematol Infect Dis. 2023 Jul 1;15(1):e2023038. doi: 10.4084/MJHID.2023.038. eCollection 2023.
世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
4
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.突变型 TP53 急性髓系白血病和高危骨髓增生异常综合征的分子特征。
Blood. 2022 Apr 14;139(15):2347-2354. doi: 10.1182/blood.2021014472.
5
Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?急性髓系白血病中的突变：仍是一项艰巨的挑战？
Front Oncol. 2021 Feb 8;10:610820. doi: 10.3389/fonc.2020.610820. eCollection 2020.
6
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.TP53 等位基因状态对骨髓增生异常综合征的基因组稳定性、临床表现和预后的影响。
Nat Med. 2020 Oct;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z. Epub 2020 Aug 3.
7
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.一线 venetoclax 联合治疗老年 AML 患者后的反应和治疗失败的分子模式。
Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.
8
Current status and new treatment approaches in TP53 mutated AML.TP53 基因突变型 AML 的现状和新的治疗方法。
Best Pract Res Clin Haematol. 2019 Jun;32(2):134-144. doi: 10.1016/j.beha.2019.05.004. Epub 2019 May 11.
9
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.TP53 基因突变状态将复杂核型骨髓增生异常综合征分为不同的预后亚组。
Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.
10
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.